Recent Material Events - Immunogen, Inc (IMGN)

Filing Date	Description
2008-09-30	(b) and (c) On September 24, 2008, the Board of Directors of ImmunoGen, Inc. (“the Company”) approved a management succession plan pursuant to which Daniel M. Junius, currently the Company’s President and Chief Operating Officer, will ...
2008-09-05	On September 5, 2008, Genentech reported trastuzumab-DM1 (T-DM1) Phase II clinical data at the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium being held in Washington, DC. T-DM1 comprises ImmunoGen’s DM1 cell-killing agent ...
2008-09-02	Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.01 par value NASDAQ Global Market ...
2008-08-01	On March 30, 2001, ImmunoGen, Inc. and Millennium Pharmaceuticals, Inc. entered into an Access, Option and License Agreement (the “Agreement”), pursua nt to which, among other things, Millennium was granted an exclusive license to ImmunoGen& ...
2008-07-31	(b) On July 29, 2008, Mitchel Sayare, Ph.D., resigned from his position as President of ImmunoGen, Inc. (the “Company”) in connection with the appointments described below. Dr. Sayare remains ImmunoGen’s Chairman of the Board and Chief ...
2008-07-15	On July 14, 2008, Genentech, Inc. disclosed new information related to trastuzumab-DM1 (T-DM1), which comprises ImmunoGen’s DM1 cell-killing agent linked to Genentech’s anti-HER2 antibody, trastuzumab. After market close, Genentech disclose ...
2008-06-23	On June 20, 2008, pursuant to a securities purchase agreement (the “Purchase Agreement”) between ImmunoGen, Inc. (the “Company”) and Ziff Asset Management, L.P. (“Ziff”), the Company issued and sold 7,812,500 shares of i ...
2008-06-09	Information regarding clinical findings reported at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL for targeted anticancer compounds IMGN242, AVE1642 and trastuzumab-DM1 (T-DM1) were announced in press releases by ...
2008-03-12	On March 11, 2008, Biotest AG announced that the Investigational New Drug (IND) application for BT-062 has been submitted to the US Food and Drug Administration (FDA) and that Biotest expects to begin clinical testing of this TAP compound in the firs ...
2007-12-17	On December 14, 2007, Genentech, Inc. presented updated Phase I clinical findings on trastuzumab-DM1 (T-DM1) at the 30th Annual San Antonio Breast Cancer Symposium (SABC). T-DM1 is an anticancer compound in development by Genentech that comprises Imm ...